A prospective, multicenter study on hematopoietic stem-cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents

Roberto Mina; Maria Teresa Petrucci; Francesca Bonello; Velia Bongarzoni; Riccardo Saccardi; Giuseppe Bertuglia; Andrea Mengarelli; Andrea Spadaro; Chiara Lisi; Paola Curci; Roberto Massimo Lemoli; Stelvio Ballanti; Rita Floris; Luca Cupelli; Patrizia Tosi; Attilio Olivieri; Delia Rota-Scalabrini; Clotilde Cangialosi; Chiara Nozzoli; Barbara Anaclerico; Francesca Fazio; Benedetto Bruno; Katia Mancuso; Paolo Corradini; Giuseppe Milone; Mario Boccadoro

doi:10.3324/haematol.2023.284023

A prospective, multicenter study on hematopoietic stem-cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents

Haematologica. 2023 Nov 16. doi: 10.3324/haematol.2023.284023. Online ahead of print.

Authors

Roberto Mina¹, Maria Teresa Petrucci², Francesca Bonello³, Velia Bongarzoni⁴, Riccardo Saccardi⁵, Giuseppe Bertuglia⁶, Andrea Mengarelli⁷, Andrea Spadaro⁸, Chiara Lisi², Paola Curci⁹, Roberto Massimo Lemoli¹⁰, Stelvio Ballanti¹¹, Rita Floris¹², Luca Cupelli¹³, Patrizia Tosi¹⁴, Attilio Olivieri¹⁵, Delia Rota-Scalabrini³, Clotilde Cangialosi¹⁶, Chiara Nozzoli⁵, Barbara Anaclerico⁴, Francesca Fazio², Benedetto Bruno⁶, Katia Mancuso¹⁷, Paolo Corradini¹⁸, Giuseppe Milone⁸, Mario Boccadoro¹⁹

Affiliations

¹ Division of Hematology, AOU Citta della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino. roberto.mina@unito.it.
² Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome.
³ Medical Oncology Department, Candiolo Cancer Institute, FPO-IRCCS, Candiolo.
⁴ U.O.C. Ematologia, Azienda Ospedaliera "San Giovanni/Addolorata", Roma.
⁵ Cellular Therapy and Transfusion Medicine Unit, Careggi University Hospital, Florence.
⁶ Division of Hematology, AOU Citta della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino.
⁷ Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome.
⁸ Division of Hematology, AOU Policlinico, University of Catania.
⁹ Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari.
¹⁰ Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genova, Italy; IRCCS Policlinico San Martino, Genova.
¹¹ Sezione di Ematologia e Immunologia Clinica, Ospedale Santa Maria della Misericordia, localita Sant'Andrea delle Fratte, Perugia.
¹² S.C. Ematologia e CTMO, Ospedale Oncologico "A. Businco", Cagliari.
¹³ Department of Hematology, S. Eugenio Hospital, Rome.
¹⁴ Hematology Unit, Infermi Hospital, Rimini.
¹⁵ Clinica di Ematologia, Azienda Ospedaliero Universitaria delle Marche, Ancona.
¹⁶ U.O.C. Ematologia, A.O. Ospedali Riuniti Villa Sofia-Cervello, Palermo.
¹⁷ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seragnoli", Bologna, Italy; Dipartimento di Scienze Mediche e Chirurgiche, Universita di Bologna, Bologna.
¹⁸ Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Universita di Milano, Milano.
¹⁹ Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino.

PMID: 37981892
DOI: 10.3324/haematol.2023.284023

Abstract

High-dose melphalan plus autologous stem-cell transplantation (ASCT) is a standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM), and adequate hematopoietic stem-cell (HSC) collection is crucial to ensure hematologic recovery after ASCT. In this prospective, observational study we evaluated HSC mobilization with granulocyte colony-stimulating factor (G-CSF), cyclophosphamide, and 'on-demand' plerixafor (in patients with.